IP Verse

Use Of Anti Cd70 Antibody Argx-110 To Treat Acute Myeloid Leukaemia

Patent No. EP3638696 (titled "Use Of Anti Cd70 Antibody Argx-110 To Treat Acute Myeloid Leukaemia") was filed by Argenx on Jun 18, 2018. The application was issued on Jun 26, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
PFIZERDec 6, 2024SCRIPT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3638696

ARGENX
Application Number
EP18732064A
Filing Date
Jun 18, 2018
Status
Granted And Under Opposition
Feb 2, 2024
Publication Date
Jun 26, 2024
External Links
Slate, Register , Google Patents